CTLA4 and Miyoshi myopathy: Since the approval of ICI, which targets Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed cell Death 1 (PD-1), the course of treatment and prognosis for metastatic melanoma (MM) have undergone significant progress.